Professor Weber’s contributions to the field of immune-oncology are legion. He worked at the forefront of new ideas in immunotherapy for treating patients with melanoma and actively managed the side effects of these novel therapies. He has been instrumental in the development of ipilimumab for melanoma, publishing some of the earliest papers showing its efficacy. He has also been an early advocate for the use of checkpoint inhibition as adjuvant treatment, culminating in the publication of the New England Journal of Medicine work showing benefit for the PD-1 antibody nivolumab compared to ipilimumab for resected high-risk melanoma. Furthermore, he has been involved in a large variety of clinical trials, including trials for melanoma vaccines, protocols involving adoptive cell therapy, and novel immunotherapy trials for patients with melanoma.

Professor Weber published more than 230 articles in the top peer-reviewed journals in his field. For his contributions to science, medicine and the treatment of cancer, he will be sorely missed.